Jundishapur Journal of Microbiology

Published by: Kowsar

Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features

Vahdat Poortahmasebi 1 , Reza Malekzadeh 2 , Ghodratollah Montazeri 2 , Ehsan Fakhari 1 , Mehdi Norouzi 1 , Azam Khamseh 1 , Masoud Mahmoodi Karkhaneh 1 , Ahmad Tavakoli 1 and Seyed Mohammad Jazayeri 1 , *
Authors Information
1 Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
2 Digestive Disease Research Center, Shariati Hospital, Tehran, IR Iran
Article information
  • Jundishapur Journal of Microbiology: September 01, 2015, 8 (9); e20262
  • Published Online: September 12, 2015
  • Article Type: Research Article
  • Received: May 28, 2014
  • Revised: September 22, 2014
  • Accepted: December 28, 2014
  • DOI: 10.5812/jjm.20262

To Cite: Poortahmasebi V, Malekzadeh R, Montazeri G, Fakhari E, Norouzi M, et al. Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features, Jundishapur J Microbiol. 2015 ; 8(9):e20262. doi: 10.5812/jjm.20262.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Matsuda K. Novel susceptibility loci for hepatocellular carcinoma in chronic HBV carriers. Hepatobiliary Surg Nutr. 2012; 1(1): 59-60[DOI][PubMed]
  • 2. Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, et al. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012; 1(6): 174-83[DOI][PubMed]
  • 3. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998; 339(2): 61-8[DOI][PubMed]
  • 4. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997; 25(1): 241-4[DOI][PubMed]
  • 5. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 2001; 33(4): 963-71[DOI][PubMed]
  • 6. Dienstag JL, Schiff ER, Mitchell M, Casey DJ, Gitlin N, Lissoos T, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology. 1999; 30(4): 1082-7[DOI][PubMed]
  • 7. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003; 36(6): 687-96[DOI][PubMed]
  • 8. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology. 2000; 32(5): 1078-88[DOI][PubMed]
  • 9. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother. 2003; 51(4): 761-85[DOI][PubMed]
  • 10. Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian SM, Merat S. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J Virol Methods. 2006; 137(2): 298-303[DOI][PubMed]
  • 11. Ghandehari F, Pourazar A, Zadeh MS, Tajedin N. Probing rate of YMDD motif mutant in lamivudine treatment of Iranian patients with chronic hepatitis B virus infection. Asian J Transfus Sci. 2011; 5(1): 32-4[DOI][PubMed]
  • 12. Afshar RM, Mollaie HR. Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using Zip nucleic acid probes in Kerman, southeast of Iran. Asian Pac J Cancer Prev. 2012; 13(8): 3657-61[PubMed]
  • 13. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989; 2(8663): 588-91[PubMed]
  • 14. Gandhe SS, Chadha MS, Walimbe AM, Arankalle VA. Hepatitis B virus: prevalence of precore/core promoter mutants in different clinical categories of Indian patients. J Viral Hepat. 2003; 10(5): 367-82[PubMed]
  • 15. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol. 1994; 68(3): 1651-9[PubMed]
  • 16. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology. 1999; 29(4): 1252-8[DOI][PubMed]
  • 17. Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S. Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Arch Virol. 1998; 143(12): 2313-26[PubMed]
  • 18. Zhong S, Chan JY, Yeo W, Tam JS, Johnson PJ. Frequent integration of precore/core mutants of hepatitis B virus in human hepatocellular carcinoma tissues. J Viral Hepat. 2000; 7(2): 115-23[PubMed]
  • 19. Gunther S, Meisel H, Reip A, Miska S, Kruger DH, Will H. Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology. 1992; 187(1): 271-9[PubMed]
  • 20. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol. 1996; 48(1): 8-16[DOI][PubMed]
  • 21. Lee YI, Hur GM, Suh DJ, Kim SH. Novel pre-C/C gene mutants of hepatitis B virus in chronic active hepatitis: naturally occurring escape mutants. J Gen Virol. 1996; 77 ( Pt 6): 1129-38[PubMed]
  • 22. Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology. 2002; 295(1): 86-96[DOI][PubMed]
  • 23. Veazjalali M, Norder H, Magnius L, Jazayeri SM, Alavian SM, Mokhtari-Azad T. A new core promoter mutation and premature stop codon in the S gene in HBV strains from Iranian patients with cirrhosis. J Viral Hepat. 2009; 16(4): 259-64[DOI][PubMed]
  • 24. Poustchi H, Mohamadkhani A, Bowden S, Montazeri G, Ayres A, Revill P, et al. Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. J Viral Hepat. 2008; 15(10): 753-60[DOI][PubMed]
  • 25. Bahramali G, Sadeghizadeh M, Amini-Bavil-Olyaee S, Alavian SM, Behzad-Behbahani A, Adeli A, et al. Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients. World J Gastroenterol. 2008; 14(35): 5448-53[PubMed]
  • 26. Mahabadi M, Norouzi M, Alavian SM, Samimirad K, Azad TM, Saberfar E, et al. Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients. Hepat Mon. 2013; 13(1)[DOI][PubMed]
  • 27. Jazayeri SM, Basuni AA, Sran N, Gish R, Cooksley G, Locarnini S, et al. HBV core sequence: definition of genotype-specific variability and correlation with geographical origin. J Viral Hepat. 2004; 11(6): 488-501[DOI][PubMed]
  • 28. Khedive A, Norouzi M, Ramezani F, Karimzadeh H, Alavian SM, Malekzadeh R, et al. Hepatitis B virus surface protein mutations clustered mainly in CTL immune epitopes in chronic carriers: results of an Iranian nationwide study. J Viral Hepat. 2013; 20(7): 494-501[DOI][PubMed]
  • 29. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 1998; 27(6): 1711-6[DOI][PubMed]
  • 30. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999; 30(2): 567-72[DOI][PubMed]
  • 31. Carman W, Thomas H, Domingo E. Viral genetic variation: hepatitis B virus as a clinical example. Lancet. 1993; 341(8841): 349-53[PubMed]
  • 32. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001; 8(5): 311-21[PubMed]
  • 33. Amini-Bavil-Olyaee S, Sarrami-Forooshani R, Adeli A, Mahboudi F, Sabahi F, Nafisi H, et al. A novel accurate amplification created restriction site method for determination of the wild type and the precore mutant hepatitis B virus variants. J Virol Methods. 2005; 127(1): 19-23[DOI][PubMed]
  • 34. Qureshi H, Arif A, Ahmed W, Alam SE. YMDD mutation in Pakistani patients. The comparison of Eastern response with the Western response. J Pak Med Assoc. 2009; 59(12): 858-9[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments